February 2023

CoV (SARS-CoV-2)

Since early 2020, a deadly pandemic caused by a new Coronavirus (SARS-CoV-2) has threatened public health, world economies, and quality of life on a global scale. As of March 2024, the COVID-19 outbreak has resulted in 775 million confirmed cases and >7 million deaths worldwide ().

Unlike the previous CoV outbreaks, which were successfully managed using public health measures, containment of SARS-CoV-2 will require a concerted effort involving vaccines and therapeutics, along with public health measures. While the successes with first generation of CoV vaccines have been remarkable, it is becoming clear that a better and long-term solution to end the current pandemic and prevent future outbreaks is desperately needed.

CURRENT SITUATION AND FUTURE NEEDS

During the COVID-19 outbreak, mutations and deletions in the Spike protein gene have produced a succession of fast spreading and pathogenic SARS-CoV-2 variants of concern (VOCs) with the potential to escape vaccine-induced immunity. Despite the deployment of >13 billion doses of CoV vaccine worldwide, COVID-19 still accounts for 3 times as many deaths as influenza. These stark numbers emphasize the need for a superior, next-generation vaccine that induces broad-based, cross-reactive, and long-lasting immunity.

Recently, the Food & Drug Administration (FDA) announced a recommendation that vaccines should be given on an annual basis, confirming the belief of the scientific community that COVID-19 with will be with us for a long time.

The Need

Vaccines were initially very effective at conferring protective immunity through the induction of neutralizing antibodies directed against spike protein. However, real-world data collected since deployment of the vaccines has demonstrated waning immunity over time and emergence of viral variants of concern (VOC) containing mutations in the spike protein with potential to escape vaccine-induced immunity. Hence, there is a pressing need to move beyond a narrow focus of immunity directed against a single viral antigen.

The Opportunity

In order to create a pre-emptive universal Coronavirus vaccine, effective against all coronavirus variants - future, current, and past - TechImmune is developing a next generation broad-spectrum vaccine targeting spike plus other more conserved antigens to elicit both neutralizing antibodies and cross-strain T cell responses.

The TechImmune Difference - Read More

The Goal

To create a pre-emptive universal Coronvirus vaccine, effective against all coronavirus variants, future, current, and past.

GRANTS AND CONTRACTS

In February 2023, TechImmune, LLC was awarded a business (SBIR) grant from the U.S. National Institute of Allergy and Infectious Diseases (NIH) to develop a Universal Vaccine Against Multiple Coronavirus Variants of Concern.

Additional grants pending Spring 2024.

Partner with us!

Contact Us